Efficiency and tolerability of 0,1% tacrolimus ointment in the treatment of patients with moderate atopic dermatitis. Effect of the medication on the skin microcirculation

Cite item


The article covers modern concepts of the influence of calcineurin inhibitors on formation and liberation inflammatory cytokines and their immunomodulating ability. Goal: to estimate efficiency and bearableness of 0,1 % Tacrolimus ointment (Protopik) at treatment of atopic dermatitis of moderate severity and eczema of hands as supporting therapy, and also influence of a preparation on microcirculation in skin. Materials and methods. In research took part 35 patients having atopic dermatitis (ATD) of moderate severity. The preparation Protopik (0,1% ointment) was used externally by daily thin layer on well cleared skin 2 times a day before clinical improvement, but not less than 2 weeks. Further, at achievement of clinical remission, it was recommended to use a preparation 2 times a week on the sites of skin which are usually struck at aggravations. In other days it was recommended to patients to use a relipidant. To patients with atopic dermatitis before the beginning of treatment and in 1 month from the beginning of application of a preparation by means of Doppler monitoring research microcirculation level in skin (volume speed of a blood-groove) was estimated. Results. High activity of a preparation as means of long supporting therapy is shown. Continuous application of a preparation within 2 weeks allows to reach in most cases almost complete remission. According to Doppler monitoring research, microcirculation in skin at patients with ATD after external application of 0,1% Tacrolimus ointment (Protopik) amplified that it is possible to explain decrease in an infiltration in a dermis. Use of a preparation differs sufficient comfort, and individual complaints to local irritation in the area where the ointment was applied were transient by nature.

Full Text

Эффективность и переносимость 0,1% мази такролимуса при лечении больных атопическим дерматитом средней степени тяжести. Влияние препарата на микроциркуляцию в коже


  1. Sulzberger M.B., Witten V.H. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952; 19: 101.
  2. Hengge U.R., Ruzicka T., Schwartz R.A. et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006; 54(1): 1—15; quiz 16—8 (ISSN: 1097—6787).
  3. Giusti F., Martella A., Bertoni L. et al. Skin barrier, Hydration, and PH of the skin of Infants Under 2 years of Age. Ped Derm 2001; 18: 93—6.
  4. Walsh P., Aeling G.L., Huff L. et al. Hypotalamuspituitary-adrenal axis suppression by superpotent steroids. J Am Acad Dermatol 1993; 29: 501—3.
  5. Veien N.K., Olholm Larsen P., Thestrup-Pedersen K. et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. BJD 1999; 140: 882—6.
  6. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis — an emerging concept. Allergy 2009; 64: 276—278.
  7. Соколовский Е.В., Монахов К.Н., Холодилова Н.А. и др. Современные подходы к лечению экземы кистей // Клин. дерматол. и венерол., 2011; 6: 40—3.
  8. Корсунская И.М., Дворянкова Е.В. Новые препараты в местной терапии атопического дерматита. Consilium Medicum 2004; 3: 4—9.
  9. Liu J., Farmer J.D. Jr, Lane W.S. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807—15.
  10. Stuetz A., Grassberg M., Meingasser J.G. Pimecrolimus (Elidel, SDZ ASM 981) — preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001 Dec; 20(4): 233—41.
  11. Ashcroft D.M., Dimmock P., Garside R. et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330: 516: originally published online 24 Feb 2005.
  12. Клинические рекомендации по ведению больных атопическим дерматитом/ (под ред. Кубановой А.А.). — М.: ДЭКС-Пресс, 2010. — 40 с.
  13. Nghiem P., Pearson G., Langley R.G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46:228—41.
  14. Baldo A., Cafiero M., D. Caterino P., D. Costanzo M. Tacrolimus ointment in the management of atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology 2009:2 1—7.
  15. Bos J.D. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003; 13: 455-61.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies